← Back to Blog|Fundraising
Fundraising2 min read11/12/2024

New AmsterdamPharma Raises $453M in Series

New AmsterdamPharma, a Biotech company based in Amsterdam, Netherlands, has raised $453M in Series at a $2B valuation led by RA Capital, RTW Investments.

FNT

Fundraising News Team

Published on 11/12/2024

New AmsterdamPharma Raises $453M in Series


New AmsterdamPharma Raises $453M in Series

New AmsterdamPharma has successfully raised $453M in a Series at a $2B valuation led by RA Capital, RTW Investments.

Company Overview

New AmsterdamPharma is a Biotech company headquartered in Amsterdam, Netherlands, founded in 2019 with 120+ employees.

Developing novel cholesterol treatment drug for cardiovascular disease

Fundraising Details

- Amount Raised: $453M
- Round Type: Series
- Valuation: $2B
- Date: 2024-11-12
- Investors: RA Capital, RTW Investments

About New AmsterdamPharma

Developing novel cholesterol treatment drug for cardiovascular disease The company is positioned in the Biotech sector, serving a growing market with innovative solutions.

Key Information

- Headquarters: Amsterdam, Netherlands
- Founded: 2019
- Team Size: 120+
- Industry: Biotech

What This Means

This funding round demonstrates strong investor confidence in New AmsterdamPharma's vision and execution. The capital will likely be used to:

- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities

Industry Context

The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. New AmsterdamPharma's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone

Reaching a $2B valuation marks an important milestone for New AmsterdamPharma, positioning the company among notable players in the Biotech industry.


Looking Ahead

With this new capital, New AmsterdamPharma is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.

---

This fundraising news was reported on 2024-11-12. For more information about New AmsterdamPharma, visit their headquarters at Amsterdam, Netherlands.

Share this article:

Related Articles

More insights from our Fundraising experts

Archive Intel Raises $6.3M in Series A
Fundraising2 min read

Archive Intel Raises $6.3M in Series A

Archive Intel, a Fintech company based in New York, NY, has raised $6.3M in Series A led by Gray Line Partners.

FNT

Fundraising News Team

10/6/2025

Upfront Raises $10M in Pre-Seed
Fundraising2 min read

Upfront Raises $10M in Pre-Seed

Upfront, a Fintech company based in Dubai, UAE, has raised $10M in Pre-Seed led by Palm Ventures, SABAH.fund.

FNT

Fundraising News Team

10/5/2025

Naveen Rao AI Hardware Raises $400M in Series A
Fundraising2 min read

Naveen Rao AI Hardware Raises $400M in Series A

Naveen Rao AI Hardware, a AI/ML company based in San Francisco, CA, has raised $400M in Series A at a $5B valuation led by Andreessen Horowitz, Lightspeed.

FNT

Fundraising News Team

10/3/2025

Ready to Transform Your Sales Process?

Join thousands of sales professionals who trust Salestools AI to drive results.

Start Free Trial